News releases - Merck.com
Oct 28, 2024 · Merck Announces Third-Quarter 2024 Financial Results. October 28, 2024. Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) October 24, 2024.
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. WINREVAIR logo (Graphic: Merck & Co., Inc.)
Merck KGaA Beats Estimates on Boost From Life Science Unit
5 hours ago · Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside positive growth trends in its other two businesses.
Merck Enters Two Strategic Collaborations to Strengthen AI …
Sep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
Feb 1, 2024 · Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel Assets Into Phase 3 in 2023. Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration Agreements With Daiichi Sankyo and Kelun-Biotech in 2023. Full-Year 2024 Financial Outlook.
News & Stories - Merck
Oct 9, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
Merck KGaA Earnings Growth Beats Expectations — Update
3 hours ago · Merck now expects 2024 net sales in the lower half of its previously expected range of 20.7 billion to 22.1 billion euros. On an organic basis, sales rose across segments. Healthcare sales rose 6. ...
FDA approves Merck's drug for rare, deadly lung condition
Mar 26, 2024 · The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients...
Merck KGaA Q3 earnings rise faster than expected on lower costs
5 hours ago · Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug development and a rebound in demand for its specialty materials.
Merck’s Covid Pill Is Authorized for High-Risk Adults - The New …
Dec 23, 2021 · Merck is expected to fulfill the federal government’s full order of enough pills for 3.1 million people, at a cost of about $700 a person, by the end of January. Pfizer is expected to provide...